New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:45 EDTGBIMGlobeImmune IPO indicated to open $11
News For GBIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
13:45 EDTGBIMGilead HBV future likely from assets other than GS-4774, says Deutsche Bank
Subscribe for More Information
06:38 EDTGBIMGlobeImmune announces top line results from GS-4774 Phase 2 trial
GlobeImmune announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term viral suppression with an oral antiviral treatment. In this study, patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy, or OAV, did not show a reduction in hepatitis B surface antigen, or HBsAg, at week 24, the primary endpoint of the study, but at 48 weeks had a mean -0.17 log10 reduction of HBsAg compared with a -0.04 log10 reduction in the OAV alone group. Three patients receiving the highest dose of GS-4774 had HBsAg reductions between -0.94 and -3.89 log10 at 48 weeks. There was no difference in HBsAg reductions between the two lowest dose groups versus the control arm at 48 weeks. Further characterization of the T cell response to GS-4774 and association with HBsAg changes are ongoing. GS-4774 was found to be generally safe and well tolerated, with injection site reactions identified as the primary adverse event. Data from this trial are expected to be submitted for future presentation and publication.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use